Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
TNGX
TNGX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TNGX News
Wall Street Analysts Adjust MU Stock Ratings
1d ago
Benzinga
Tango Therapeutics Grants Stock Options and RSUs to New Employee
3d ago
Newsfilter
Tango Therapeutics Shares Surge 24% to New 52-Week High Following Collaboration with Erasca
5d ago
seekingalpha
Health Care Stocks Decline, NYSE Health Care Index Drops 2.3%
5d ago
Yahoo Finance
Tango Therapeutics Q4 Earnings Beat Expectations
5d ago
seekingalpha
Erasca Partners with Tango for Clinical Trial of ERAS-0015
5d ago
Newsfilter
Boxer Capital Increases Stake in Tango Therapeutics
5d ago
Fool
Boxer Capital Increases Stake in Tango Therapeutics
5d ago
NASDAQ.COM
Wall Street's First Trading Day of March Outlook
Mar 01 2026
CNBC
Tango Therapeutics CEO Barbara Weber Retires; Malte Peters Appointed as New CEO
Jan 08 2026
Globenewswire
5 Biotech Stocks to Keep an Eye On for Possible Growth
Dec 17 2025
NASDAQ.COM
Tango Therapeutics CEO to Present at 2026 J.P. Morgan Healthcare Conference
Dec 17 2025
Globenewswire
Is Tango Therapeutics (TNGX) Overpriced Following a 200% Increase in the Past Year? An Updated Analysis of Its Valuation
Dec 14 2025
Yahoo Finance
Oncolytics Biotech Secures FDA Approval for Phase 3 Immunotherapy Trial in Pancreatic Cancer
Dec 12 2025
PRnewswire
Oncolytics Biotech Secures FDA Approval for Phase 3 Immunotherapy Trial in Pancreatic Cancer
Dec 12 2025
Newsfilter
Tango Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
Nov 26 2025
Globenewswire
Show More News
